



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Aripiprazole N-oxide

Item No. 35296

CAS Registry No.: 573691-09-5
Formal Name: 7-[4-[4-(2,3-dichlorophenyl)-1-oxido-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone
Synonym: Aripiprazole N1-Oxide
MF: C₂₃H₂₇Cl₂N₃O₃
FW: 464.4
Purity: ≥90%
UV/Vis.: λ_{max}: 218 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Aripiprazole N-oxide is supplied as a solid. A stock solution may be made by dissolving the aripiprazole N-oxide in the solvent of choice, which should be purged with an inert gas. Aripiprazole N-oxide is soluble in DMSO.

Description

Aripiprazole N-oxide is a metabolite of the atypical antipsychotic aripiprazole (Item No. 19989).^{1,2} It is formed from aripiprazole by the cytochrome P450 (CYP) isoforms CYP2D6 and CYP3A4.² Aripiprazole N-oxide is a potential impurity found in commercial preparations of aripiprazole.¹

References

1. Filijovic, N.D., Pavlović, A., Nikolic, K., *et al.* Validation of an HPLC method for determination of aripiprazole and its impurities in pharmaceuticals. *Acta Chromatogr.* **26(1)**, 13-28 (2014).
2. Satyanarayana, B., Sumalatha, Y., Kumar, S.S., *et al.* Synthesis and characterization of N-oxides and metabolites of antipsychotic drug, aripiprazole. *Heterocycl. Commun.* **11(6)**, 485-490 (2005).
3. Kubo, M., Koue, T., Inaba, A., *et al.* Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. *Drug Metab. Pharmacokinet.* **20(1)**, 55-64 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM